Your browser doesn't support javascript.
loading
Folic Acid-Modified Ibrutinib-Loaded Silk Fibroin Nanoparticles for Cancer Cell Therapy with Over-Expressed Folate Receptor.
Fuster, Marta G; Montalbán, Mercedes G; Moulefera, Imane; Víllora, Gloria; Kaplan, David L.
Afiliação
  • Fuster MG; Department of Chemical Engineering, Faculty of Chemistry, University of Murcia (UMU), Campus de Espinardo, 30100 Murcia, Spain.
  • Montalbán MG; Department of Chemical Engineering, Faculty of Chemistry, University of Murcia (UMU), Campus de Espinardo, 30100 Murcia, Spain.
  • Moulefera I; Department of Chemical Engineering, Faculty of Chemistry, University of Murcia (UMU), Campus de Espinardo, 30100 Murcia, Spain.
  • Víllora G; Department of Chemical Engineering, Faculty of Chemistry, University of Murcia (UMU), Campus de Espinardo, 30100 Murcia, Spain.
  • Kaplan DL; Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.
Pharmaceutics ; 15(4)2023 Apr 07.
Article em En | MEDLINE | ID: mdl-37111671
ABSTRACT
The anticancer drug ibrutinib (IB), also known as PCI-32765, is a compound that irreversibly inhibits Bruton's tyrosine kinase (BTK) and was initially developed as a treatment option for B-cell lineage neoplasms. Its action is not limited to B-cells, as it is expressed in all hematopoietic lineages and plays a crucial role in the tumor microenvironment. However, clinical trials with the drug have resulted in conflicting outcomes against solid tumors. In this study, folic acid-conjugated silk nanoparticles were used for the targeted delivery of IB to the cancer cell lines HeLa, BT-474, and SKBR3 by exploiting the overexpression of folate receptors on their surfaces. The results were compared with those of control healthy cells (EA.hy926). Cellular uptake studies confirmed total internalization of the nanoparticles functionalized by this procedure in the cancer cells after 24 h, compared to nanoparticles not functionalized with folic acid, suggesting that cellular uptake was mediated by folate receptors overexpressed in the cancer cells. The results indicate that the developed nanocarrier can be used for drug targeting applications by enhancing IB uptake in cancer cells with folate receptor overexpression.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceutics Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceutics Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha
...